BIOTECHNOLOGY: Wrangle over Wonder Drugs

Wrangle over Wonder Drugs

Who owns the wonder drugs that the biotechnology industry creates through genetic engineering? This is turning out to be a thorny question. As a result, firms may have trouble getting widespread patent protection for their new products. South San Francisco-based Genentech last week lost a significant legal battle when a British high court failed to uphold a patent that the company had received in Britain on t-PA, a substance that dissolves blood clots, a cause of heart attacks. Some industry experts think the British case could be a harbinger of more patent troubles for biotech firms. In the aftermath of the...

Want the full story?

Subscribe Now

Subscribe
Subscribe

Get TIME the way you want it

  • One Week Digital Pass — $4.99
  • Monthly Pay-As-You-Go DIGITAL ACCESS$2.99
  • One Year ALL ACCESSJust $30!   Best Deal!
    Print Magazine + Digital Edition + Subscriber-only Content on TIME.com

Learn more about the benefits of being a TIME subscriber

If you are already a subscriber sign up — registration is free!